metformin has been researched along with Barrett Esophagus in 7 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Barrett Esophagus: A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups." | 5.72 | Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022) |
| "Metformin use was neither associated with an increased nor a decreased risk of esophageal cancer." | 5.40 | Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014) |
| "Metformin was associated with an almost significant reduction in serum levels of insulin (median -4." | 2.80 | Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. ( Buttar, NS; Chak, A; Cruz-Correa, MR; Falk, GW; Foster, NR; Hur, C; Katzka, DA; Limburg, PJ; Mandrekar, SJ; Marcon, NE; Richmond, E; Rodriguez, LM; Schoen, R; Seisler, DK; Sharma, AN; Sharma, P; Smyrk, TC, 2015) |
| "Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin." | 2.72 | Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021) |
| "Chemoprevention in Barrett's esophagus is currently applied only in research settings." | 2.52 | Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015) |
| "To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups." | 1.72 | Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022) |
| " Chronic use of other common drugs, namely, statins nonsteroidal anti-inflammatory drugs (NSAIDs) and metformin, may also interfere with BE carcinogenesis, but confirmatory evidence is lacking." | 1.62 | Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis. ( Chaloux, M; Loomans-Kropp, HA; Richmond, E; Umar, A, 2021) |
| "BE subjects developing esophageal cancer (EC) 12 months after their index BE diagnosis were defined as progressors." | 1.43 | Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. ( Borah, B; Chak, A; Das, A; Heien, H; Iyer, PG; Krishnamoorthi, R, 2016) |
| "Metformin use was neither associated with an increased nor a decreased risk of esophageal cancer." | 1.40 | Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Loomans-Kropp, HA | 1 |
| Chaloux, M | 1 |
| Richmond, E | 2 |
| Umar, A | 1 |
| Moayyedi, P | 1 |
| El-Serag, HB | 1 |
| Takei, R | 1 |
| Miyashita, T | 1 |
| Takada, S | 1 |
| Tajima, H | 1 |
| Ninomiya, I | 1 |
| Takamura, H | 1 |
| Fushida, S | 1 |
| Harashima, A | 1 |
| Munesue, S | 1 |
| Yagi, S | 1 |
| Inaki, N | 1 |
| Ohta, T | 1 |
| Yamamoto, Y | 1 |
| Chak, A | 2 |
| Buttar, NS | 2 |
| Foster, NR | 1 |
| Seisler, DK | 1 |
| Marcon, NE | 1 |
| Schoen, R | 1 |
| Cruz-Correa, MR | 1 |
| Falk, GW | 1 |
| Sharma, P | 1 |
| Hur, C | 1 |
| Katzka, DA | 1 |
| Rodriguez, LM | 1 |
| Sharma, AN | 1 |
| Smyrk, TC | 1 |
| Mandrekar, SJ | 1 |
| Limburg, PJ | 1 |
| Agrawal, S | 1 |
| Patel, P | 1 |
| Agrawal, A | 1 |
| Makhijani, N | 1 |
| Markert, R | 1 |
| Deidrich, W | 1 |
| Zeb, MH | 1 |
| Baruah, A | 1 |
| Kossak, SK | 1 |
| Krishnamoorthi, R | 1 |
| Borah, B | 1 |
| Heien, H | 1 |
| Das, A | 1 |
| Iyer, PG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin[NCT01447927] | Phase 2 | 93 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percent change in pS6K1 was calculated as month 3 pS6k1 values minus baseline pS6k1 values, then divide by baseline pS6k1 values and multiply by 100. (NCT01447927)
Timeframe: Baseline to 3 months
| Intervention | percentage of change (Median) |
|---|---|
| Metformin | 1.4 |
| Placebo | -14.7 |
"Number of patients that experienced adverse events (grade 1 or above) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v. 4.0.~The data reported in the table include only the commonly occurring adverse events (3 or more events)." (NCT01447927)
Timeframe: Up to 30 days
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal Pain | Cough | Diarrhea | Dyspepsia | Fatigue | Flatulence | Flu like symptoms | Gastrointestinal disorders - other, specify | Headache | Nausea | |
| Metformin | 6 | 0 | 10 | 2 | 4 | 2 | 1 | 2 | 3 | 5 |
| Placebo | 0 | 3 | 5 | 3 | 1 | 2 | 2 | 2 | 2 | 3 |
2 reviews available for metformin and Barrett Esophagus
| Article | Year |
|---|---|
Current Status of Chemoprevention in Barrett's Esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N | 2021 |
Chemoprevention in Barrett's Esophagus: Current Status.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy | 2015 |
1 trial available for metformin and Barrett Esophagus
| Article | Year |
|---|---|
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Cell Proliferation; Double-Blind Method; Endoscop | 2015 |
4 other studies available for metformin and Barrett Esophagus
| Article | Year |
|---|---|
Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; | 2021 |
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Carcinogenesis; Esophageal Neoplasms; Metformin; Rats; T | 2022 |
Metformin use and the risk of esophageal cancer in Barrett esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Case-Control Studies; Diabetes Me | 2014 |
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Topics: Adenocarcinoma; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Body | 2016 |